Partner with us to speed up the development of Structurally Nanoengineered Antimicrobial Peptide Polymers (or SNAPP) anti-bacterial technology.
Explore opportunities for licensing or direct investment.
The technology
University of Melbourne researchers have created star-shaped polypeptides. These are Structurally Nanoengineered Antimicrobial Peptide Polymers, or SNAPPs. They have anti-bacterial properties, including against multi-drug-resistant (MD)R bacteria.
SNAPPs also have adjuvant activity, improving the efficiency of existing antibiotics.
Market need
Multi-drug resistant bacteria are a threat to human health. The infections they cause are harder to treat than those caused by non-resistant bacteria, so development of novel anti-bacterial therapies is a global health priority.
Technology status
Proof-of-concept has been achieved using various in vitro microscopy and bioassay studies. These show SNAPPs’ antimicrobial activity, mode of action and low toxicity.
Contact
Eric Hoefgen
eric.hoefgen@unimelb.edu.au
Phone: +61 3 8344 4519
Flyer
Download flyer for more information (PDF)
Keep reading
-
Negotiating a licence with the University
By licensing the University of Melbourne’s intellectual property (IP) and technologies, you can harness research discoveries to solve business challenges.
-
Our IP principles
Our Intellectual Property (IP) management principles make it easier to collaborate with us.
-
Investing in University startups
Find out about new ways to invest in University startups
-
Contact
From developing an idea to finding startup funding, the University of Melbourne’s team of experts can help.